<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ozempic Side Effects: Short-Term, Long-Term, and What to Expect</title>
    <meta name="description" content="Complete guide to Ozempic side effects — common GI symptoms, serious risks, long-term concerns, and when to call your doctor. Includes side effect comparison table.">
    <link rel="canonical" href="https://ozempic.md/side-effects-long-term">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ozempic.md/side-effects-long-term">
    <meta property="og:title" content="Ozempic Side Effects: Short-Term, Long-Term, and What to Expect">
    <meta property="og:description" content="Complete guide to Ozempic side effects — common GI symptoms, serious risks, long-term concerns, and when to call your doctor.">
    <meta property="og:site_name" content="ozempic.md">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="ai-content" content="allowed">
    <meta name="ai-topic" content="ozempic side effects, semaglutide adverse effects, GLP-1 safety">

    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "MedicalWebPage",
          "@id": "https://ozempic.md/side-effects-long-term#webpage",
          "name": "Ozempic Side Effects: Short-Term, Long-Term, and What to Expect",
          "description": "Evidence-based guide to Ozempic (semaglutide) side effects including common GI symptoms, serious risks, and long-term safety data.",
          "url": "https://ozempic.md/side-effects-long-term",
          "isPartOf": {"@id": "https://ozempic.md/#website"},
          "lastReviewed": "2026-02-01",
          "reviewedBy": {"@type": "Person", "name": "Dr. Agustin Arrieta", "jobTitle": "MD"},
          "mainEntity": {
            "@type": "Drug",
            "name": "Ozempic",
            "activeIngredient": "Semaglutide",
            "drugClass": "GLP-1 receptor agonist",
            "adverseOutcome": [
              {"@type": "MedicalEntity", "name": "Nausea"},
              {"@type": "MedicalEntity", "name": "Vomiting"},
              {"@type": "MedicalEntity", "name": "Diarrhea"},
              {"@type": "MedicalEntity", "name": "Constipation"},
              {"@type": "MedicalEntity", "name": "Pancreatitis"},
              {"@type": "MedicalEntity", "name": "Gallbladder disease"}
            ],
            "manufacturer": {"@type": "Organization", "name": "Novo Nordisk"}
          }
        },
        {
          "@type": "FAQPage",
          "@id": "https://ozempic.md/side-effects-long-term#faq",
          "mainEntity": [
            {
              "@type": "Question",
              "name": "What are the most common side effects of Ozempic?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "The most common side effects are gastrointestinal: nausea (15-20%), diarrhea (8.5%), vomiting (5-9%), constipation (3-5%), and abdominal pain (5-7%). These are most prominent during dose escalation and typically improve within 4-8 weeks."
              }
            },
            {
              "@type": "Question",
              "name": "Do Ozempic side effects go away?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Most GI side effects (nausea, vomiting, diarrhea) improve significantly within 4-8 weeks as your body adjusts. Gradual dose escalation helps minimize these effects. About 5% of patients in clinical trials discontinued due to GI side effects."
              }
            },
            {
              "@type": "Question",
              "name": "What are the serious long-term risks of Ozempic?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Serious but rare risks include pancreatitis (inflammation of the pancreas), gallbladder problems including gallstones, potential thyroid tumor risk (observed in animals but not confirmed in humans), diabetic retinopathy complications, and acute kidney injury, usually from dehydration due to GI side effects."
              }
            },
            {
              "@type": "Question",
              "name": "Can Ozempic cause pancreatitis?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Pancreatitis has been reported in patients taking Ozempic, though the incidence is low (less than 1%). In the SUSTAIN clinical trials, pancreatitis occurred in 0.1-0.3% of semaglutide-treated patients. Symptoms include severe abdominal pain radiating to the back, nausea, and vomiting. Seek immediate medical attention if you experience these symptoms."
              }
            },
            {
              "@type": "Question",
              "name": "Does Ozempic cause thyroid cancer?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "In rodent studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. This has not been confirmed in humans. The FDA has placed a boxed warning on Ozempic for this risk. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."
              }
            },
            {
              "@type": "Question",
              "name": "When should I call my doctor about Ozempic side effects?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Call your doctor immediately if you experience: severe abdominal pain that doesn't go away (possible pancreatitis), vision changes (possible retinopathy complications), signs of kidney problems (decreased urination, swelling), signs of allergic reaction (swelling of face/throat, difficulty breathing), or a lump in your neck (possible thyroid issue)."
              }
            },
            {
              "@type": "Question",
              "name": "Does Ozempic cause muscle loss?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Weight loss on Ozempic, like any caloric deficit, includes some lean muscle mass loss — typically 30-40% of total weight lost is lean mass. This is consistent with weight loss from any method. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) can help minimize muscle loss."
              }
            },
            {
              "@type": "Question",
              "name": "Can Ozempic cause depression or mood changes?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "The FDA is investigating reports of suicidal thoughts and self-harm with GLP-1 receptor agonists, though a causal link has not been established. Large-scale analyses, including a 2024 study in Nature Medicine, have not found increased depression or suicidality with semaglutide compared to other treatments. Report any mood changes to your doctor."
              }
            }
          ]
        }
      ]
    }
    </script>

    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root { --bg-primary: #ffffff; --bg-secondary: #f8fafc; --bg-tertiary: #f1f5f9; --text-primary: #0f172a; --text-secondary: #475569; --text-muted: #94a3b8; --accent: #0d9488; --accent-dark: #0f766e; --accent-light: #ccfbf1; --border: #e2e8f0; --font-display: 'Source Serif 4', Georgia, serif; --font-body: 'Inter', -apple-system, sans-serif; }
        html { scroll-behavior: smooth; } * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.7; font-size: 16px; }
        header { position: fixed; top: 0; left: 0; right: 0; z-index: 100; background: rgba(255,255,255,0.95); backdrop-filter: blur(10px); border-bottom: 1px solid var(--border); }
        .header-inner { max-width: 1100px; margin: 0 auto; padding: 16px 24px; display: flex; justify-content: space-between; align-items: center; }
        .logo { font-family: var(--font-display); font-size: 22px; font-weight: 600; color: var(--text-primary); text-decoration: none; }
        .logo span { color: var(--accent); }
        nav { display: flex; gap: 32px; } nav a { color: var(--text-secondary); text-decoration: none; font-size: 14px; font-weight: 500; transition: color 0.2s; } nav a:hover { color: var(--accent); }
        .article-hero { padding: 120px 24px 48px; max-width: 720px; margin: 0 auto; }
        .breadcrumb { font-size: 13px; color: var(--text-muted); margin-bottom: 16px; } .breadcrumb a { color: var(--accent); text-decoration: none; } .breadcrumb a:hover { text-decoration: underline; }
        .article-hero h1 { font-family: var(--font-display); font-size: clamp(32px, 5vw, 44px); font-weight: 700; line-height: 1.2; margin-bottom: 16px; }
        .article-meta { display: flex; flex-wrap: wrap; gap: 16px; align-items: center; font-size: 13px; color: var(--text-muted); margin-bottom: 8px; }
        .review-badge { display: inline-flex; align-items: center; gap: 6px; background: var(--accent-light); color: var(--accent-dark); padding: 4px 12px; border-radius: 100px; font-size: 12px; font-weight: 600; }
        main { max-width: 720px; margin: 0 auto; padding: 0 24px 64px; }
        .section { margin-bottom: 48px; }
        .section-label { font-size: 12px; font-weight: 600; color: var(--accent); text-transform: uppercase; letter-spacing: 1px; margin-bottom: 12px; }
        h2 { font-family: var(--font-display); font-size: 28px; font-weight: 700; margin-bottom: 16px; color: var(--text-primary); }
        h3 { font-family: var(--font-display); font-size: 22px; font-weight: 600; margin-bottom: 12px; color: var(--text-primary); margin-top: 32px; }
        main p { font-size: 17px; color: var(--text-secondary); margin-bottom: 16px; line-height: 1.8; }
        main ul, main ol { margin: 0 0 16px 24px; color: var(--text-secondary); font-size: 17px; line-height: 1.8; } main li { margin-bottom: 8px; }
        .info-box { background: var(--accent-light); border: 1px solid #99f6e4; border-left: 4px solid var(--accent); border-radius: 8px; padding: 20px; margin: 24px 0; }
        .info-box h4 { font-family: var(--font-display); font-size: 16px; font-weight: 600; margin-bottom: 8px; color: var(--accent-dark); }
        .info-box p { font-size: 15px; color: var(--accent-dark); margin-bottom: 0; }
        .warning-box { background: #fef2f2; border: 1px solid #fecaca; border-left: 4px solid #ef4444; border-radius: 8px; padding: 20px; margin: 24px 0; }
        .warning-box h4 { font-family: var(--font-display); font-size: 16px; font-weight: 600; margin-bottom: 8px; color: #991b1b; }
        .warning-box p, .warning-box ul { font-size: 15px; color: #7f1d1d; margin-bottom: 0; line-height: 1.7; }
        .warning-box li { margin-bottom: 4px; }
        .comparison-table { width: 100%; border-collapse: collapse; margin: 24px 0; border: 1px solid var(--border); border-radius: 8px; overflow: hidden; }
        .comparison-table thead { background: var(--bg-secondary); }
        .comparison-table th { padding: 12px 16px; text-align: left; font-size: 13px; font-weight: 600; color: var(--text-primary); border-bottom: 1px solid var(--border); }
        .comparison-table td { padding: 12px 16px; font-size: 14px; color: var(--text-secondary); border-bottom: 1px solid var(--border); }
        .comparison-table tr:last-child td { border-bottom: none; }
        .faq-section { background: var(--bg-secondary); border-radius: 12px; padding: 32px; margin: 48px 0; }
        .faq-section h2 { font-size: 24px; margin-bottom: 24px; }
        .faq-item { border-bottom: 1px solid var(--border); padding: 16px 0; }
        .faq-item:last-child { border-bottom: none; }
        .faq-question { font-weight: 600; font-size: 16px; color: var(--text-primary); margin-bottom: 8px; }
        .faq-answer { font-size: 15px; color: var(--text-secondary); line-height: 1.7; }
        .sources { margin-top: 48px; padding-top: 32px; border-top: 1px solid var(--border); }
        .sources h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .sources ol { font-size: 14px; color: var(--text-muted); line-height: 1.8; }
        .sources a { color: var(--accent); text-decoration: none; } .sources a:hover { text-decoration: underline; }
        .related-articles { margin-top: 48px; padding: 32px; background: var(--bg-secondary); border-radius: 12px; }
        .related-articles h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .related-articles a { display: block; color: var(--accent); text-decoration: none; font-size: 15px; margin-bottom: 8px; font-weight: 500; }
        .related-articles a:hover { text-decoration: underline; }
        footer { background: var(--bg-secondary); border-top: 1px solid var(--border); padding: 48px 24px; }
        .footer-inner { max-width: 1100px; margin: 0 auto; text-align: center; }
        .footer-inner p { font-size: 14px; color: var(--text-muted); margin-bottom: 8px; } .footer-inner a { color: var(--accent); text-decoration: none; }
        @media (max-width: 768px) { nav { display: none; } .article-hero { padding: 100px 16px 32px; } .article-hero h1 { font-size: 28px; } main { padding: 0 16px 48px; } .faq-section { padding: 20px; } .comparison-table th, .comparison-table td { padding: 8px 10px; font-size: 12px; } }
    </style>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="https://ozempic.md" class="logo">ozempic<span>.md</span></a>
            <nav>
                <a href="https://ozempic.md">Home</a>
                <a href="https://ozempic.md/how-ozempic-works">How It Works</a>
                <a href="https://ozempic.md/ozempic-cost">Cost</a>
                <a href="https://ozempic.md/ozempic-vs-mounjaro">vs Mounjaro</a>
            </nav>
        </div>
    </header>

    <div class="article-hero">
        <div class="breadcrumb"><a href="https://ozempic.md">Home</a> → Side Effects</div>
        <h1>Ozempic Side Effects: Short-Term, Long-Term, and What to Expect</h1>
        <div class="article-meta">
            <span class="review-badge">✓ Medically reviewed by Dr. Agustin Arrieta, MD</span>
            <span>Last updated: February 2026</span>
        </div>
    </div>

    <main>
        <div class="section">
            <p>Ozempic (semaglutide) is generally well-tolerated, but like all medications, it comes with side effects. Some are common and temporary. Others are rare but serious. Knowing what to expect — and when to be concerned — helps you use the medication safely and make informed decisions with your healthcare provider.</p>
            <p>This guide covers everything from the first-week nausea to long-term safety data, drawn from clinical trials involving over 8,000 patients and post-marketing surveillance.</p>
        </div>

        <div class="section">
            <div class="section-label">Common Side Effects</div>
            <h2>What Most People Experience</h2>

            <p>The most frequently reported side effects are gastrointestinal, occurring primarily during the dose-escalation phase (first 8-16 weeks). These are a direct consequence of how the drug works — slowing gastric emptying and altering gut signaling.</p>

            <table class="comparison-table">
                <thead>
                    <tr><th>Side Effect</th><th>Frequency</th><th>Typical Duration</th><th>Management</th></tr>
                </thead>
                <tbody>
                    <tr><td><strong>Nausea</strong></td><td>15–20%</td><td>4–8 weeks</td><td>Eat smaller meals, avoid fatty/fried foods, stay hydrated</td></tr>
                    <tr><td><strong>Diarrhea</strong></td><td>8–9%</td><td>2–6 weeks</td><td>Stay hydrated, avoid high-fiber and spicy foods initially</td></tr>
                    <tr><td><strong>Vomiting</strong></td><td>5–9%</td><td>2–4 weeks</td><td>Eat bland foods, avoid large meals, contact doctor if persistent</td></tr>
                    <tr><td><strong>Constipation</strong></td><td>3–5%</td><td>Variable</td><td>Increase water and fiber intake, consider stool softener</td></tr>
                    <tr><td><strong>Abdominal pain</strong></td><td>5–7%</td><td>2–6 weeks</td><td>Eat slowly, reduce portion sizes</td></tr>
                    <tr><td><strong>Injection site reactions</strong></td><td>0.2%</td><td>Hours to days</td><td>Rotate injection sites, apply cold compress</td></tr>
                    <tr><td><strong>Headache</strong></td><td>1–3%</td><td>1–2 weeks</td><td>Stay hydrated, OTC pain relief as needed</td></tr>
                    <tr><td><strong>Fatigue</strong></td><td>1–3%</td><td>Variable</td><td>Ensure adequate caloric intake, rest</td></tr>
                </tbody>
            </table>

            <div class="info-box">
                <h4>The Good News</h4>
                <p>For the majority of patients, GI side effects peak during the first dose escalation and improve substantially by week 8. In the SUSTAIN trials, only about 4-5% of patients discontinued semaglutide due to GI side effects — meaning 95% found them manageable.</p>
            </div>

            <h3>Why Nausea Happens — and Why It Fades</h3>
            <p>Nausea is the hallmark side effect of GLP-1 agonists. It occurs because semaglutide slows gastric emptying and activates nausea-related receptors in the brainstem (area postrema). As your body adjusts to the medication — a process called tachyphylaxis — these receptors become less sensitive, and nausea diminishes.</p>
            <p>This is precisely why the dosing schedule is gradual: starting at 0.25 mg (a sub-therapeutic dose) for 4 weeks gives your GI system time to adapt before moving to the therapeutic 0.5 mg dose.</p>
        </div>

        <div class="section">
            <div class="section-label">Serious Side Effects</div>
            <h2>Rare but Important Risks</h2>

            <p>While uncommon, these side effects require medical attention:</p>

            <h3>Pancreatitis</h3>
            <p>Inflammation of the pancreas has been reported in 0.1-0.3% of patients taking semaglutide in clinical trials. Symptoms include severe, persistent abdominal pain (often radiating to the back), nausea, and vomiting. The mechanism is not fully understood but may relate to GLP-1's effects on pancreatic duct cells. Patients with a history of pancreatitis should discuss this risk carefully with their provider.</p>

            <h3>Gallbladder Disease</h3>
            <p>Rapid weight loss from any cause increases the risk of gallstones. In the SUSTAIN and STEP trials, cholelithiasis (gallstones) occurred in 1.5-2.6% of semaglutide-treated patients compared to 0.4-1.0% on placebo. Symptoms include right upper abdominal pain, especially after fatty meals, and nausea. Some cases required cholecystectomy (gallbladder removal).</p>

            <h3>Acute Kidney Injury</h3>
            <p>Reported in post-marketing surveillance, typically secondary to dehydration from severe vomiting or diarrhea. Patients with pre-existing kidney disease are at higher risk. Monitoring kidney function and maintaining adequate hydration are important, especially during dose escalation when GI symptoms are most likely.</p>

            <h3>Diabetic Retinopathy Complications</h3>
            <p>SUSTAIN 6 found a statistically significant increase in diabetic retinopathy complications (3.0% vs 1.8% on placebo). This is thought to be related to the speed of blood sugar improvement rather than a direct drug effect — rapid A1C reduction can temporarily worsen existing retinopathy. Patients with existing diabetic retinopathy should have eye exams before starting and during treatment.</p>

            <h3>Hypoglycemia</h3>
            <p>When used alone, Ozempic carries a low risk of hypoglycemia due to its glucose-dependent mechanism. However, when combined with insulin or sulfonylureas, the risk increases significantly. Dose adjustments of those medications may be necessary.</p>
        </div>

        <div class="section">
            <div class="section-label">Boxed Warning</div>
            <h2>Thyroid C-Cell Tumor Risk</h2>

            <div class="warning-box">
                <h4>⚠️ FDA Boxed Warning</h4>
                <p>In rodent studies, semaglutide caused dose-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Ozempic is contraindicated in patients with:</p>
                <ul style="margin: 8px 0 0 20px;">
                    <li>A personal or family history of MTC</li>
                    <li>Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)</li>
                </ul>
            </div>

            <p>It's important to note that the relevance to humans remains uncertain. Rodent thyroid C-cells have a much higher density of GLP-1 receptors than human C-cells, making the rodent model imperfect for predicting human risk. Large epidemiological studies and the SUSTAIN trial program have not detected an increased rate of MTC in humans. However, the risk cannot be fully excluded, which is why the boxed warning remains.</p>
            <p>Report any lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath to your healthcare provider immediately.</p>
        </div>

        <div class="section">
            <div class="section-label">Long-Term Safety</div>
            <h2>What We Know After Years of Data</h2>

            <p>Semaglutide has been on the market since 2017 (Ozempic) and studied in clinical trials since 2012. The long-term safety profile is reassuring for most patients, but some areas are still under investigation:</p>

            <h3>Confirmed Long-Term Safety</h3>
            <ul>
                <li><strong>Cardiovascular:</strong> SUSTAIN 6 and SELECT trial data demonstrate cardiovascular benefit, not harm, over 2-5 years</li>
                <li><strong>Metabolic:</strong> Sustained A1C reductions and weight loss maintained over 2+ years of continuous use</li>
                <li><strong>No increased cancer risk:</strong> Large-scale analyses have not found increased overall cancer incidence with GLP-1 agonists in humans</li>
            </ul>

            <h3>Areas Still Under Study</h3>
            <ul>
                <li><strong>Thyroid cancer risk in humans:</strong> No signal detected, but ongoing monitoring continues</li>
                <li><strong>Pancreatic cancer:</strong> No causal association established, but monitoring continues given theoretical concerns</li>
                <li><strong>Mental health effects:</strong> FDA investigating reports of suicidal ideation with GLP-1 agonists. Large studies to date (including a 2024 <em>Nature Medicine</em> analysis) have not found increased risk</li>
                <li><strong>Bone density:</strong> Rapid weight loss can affect bone density; long-term effects of GLP-1-associated weight loss on fracture risk remain under study</li>
                <li><strong>Muscle mass:</strong> Weight loss includes 30-40% lean mass. Long-term impact on sarcopenia risk is being evaluated</li>
            </ul>
        </div>

        <div class="section">
            <div class="section-label">Side Effects by Dose</div>
            <h2>Comparison Across Doses</h2>

            <table class="comparison-table">
                <thead>
                    <tr><th>Side Effect</th><th>0.25 mg</th><th>0.5 mg</th><th>1 mg</th><th>2 mg</th></tr>
                </thead>
                <tbody>
                    <tr><td>Nausea</td><td>7%</td><td>12%</td><td>16%</td><td>20%</td></tr>
                    <tr><td>Diarrhea</td><td>4%</td><td>6%</td><td>8%</td><td>9%</td></tr>
                    <tr><td>Vomiting</td><td>2%</td><td>4%</td><td>6%</td><td>9%</td></tr>
                    <tr><td>Constipation</td><td>2%</td><td>3%</td><td>4%</td><td>5%</td></tr>
                    <tr><td>Abdominal pain</td><td>3%</td><td>5%</td><td>6%</td><td>7%</td></tr>
                    <tr><td>Discontinuation due to AEs</td><td>1%</td><td>3%</td><td>4%</td><td>5%</td></tr>
                </tbody>
            </table>
            <p style="font-size: 13px; color: var(--text-muted);">Data from SUSTAIN trial program. Percentages are approximate and vary across trials.</p>
        </div>

        <div class="section">
            <div class="section-label">When to Seek Help</div>
            <h2>When to Call Your Doctor</h2>

            <div class="warning-box">
                <h4>Seek Immediate Medical Attention If You Experience:</h4>
                <ul style="margin: 8px 0 0 20px;">
                    <li><strong>Severe abdominal pain</strong> that doesn't go away — may indicate pancreatitis</li>
                    <li><strong>Signs of allergic reaction</strong> — swelling of face, lips, tongue, or throat; difficulty breathing; rash</li>
                    <li><strong>Vision changes</strong> — blurred vision, floaters, or sudden vision loss (possible retinopathy complications)</li>
                    <li><strong>Kidney problems</strong> — decreased urination, swelling in feet/ankles, confusion</li>
                    <li><strong>Lump in your neck</strong> — possible thyroid issue, especially with hoarseness or difficulty swallowing</li>
                    <li><strong>Signs of severe hypoglycemia</strong> — shakiness, rapid heartbeat, confusion, loss of consciousness</li>
                </ul>
            </div>

            <p><strong>Contact your doctor (non-emergency) if:</strong></p>
            <ul>
                <li>Nausea, vomiting, or diarrhea is persistent (lasting more than 3 days) or severe enough to prevent eating/drinking</li>
                <li>You notice unexplained mood changes, anxiety, or depressive symptoms</li>
                <li>You experience right upper abdominal pain after eating (possible gallstones)</li>
                <li>You have heart rate changes (semaglutide can increase resting heart rate by 1-4 bpm on average)</li>
                <li>You notice significant hair thinning (may indicate telogen effluvium from rapid weight loss)</li>
            </ul>
        </div>

        <div class="section">
            <div class="section-label">Practical Tips</div>
            <h2>Managing Side Effects</h2>

            <h3>During Dose Escalation (First 8-16 Weeks)</h3>
            <ul>
                <li><strong>Eat smaller, more frequent meals</strong> — 4-5 small meals instead of 3 large ones</li>
                <li><strong>Avoid trigger foods</strong> — fatty, fried, greasy, and very spicy foods worsen nausea</li>
                <li><strong>Stay hydrated</strong> — sip water throughout the day. Dehydration from GI symptoms is the most common cause of complications</li>
                <li><strong>Time your injection</strong> — some patients find injecting in the evening helps them sleep through initial nausea</li>
                <li><strong>Don't skip the starting dose</strong> — 0.25 mg for 4 weeks isn't optional. It lets your body adjust</li>
                <li><strong>Ginger can help</strong> — ginger tea or supplements have evidence for nausea relief</li>
            </ul>

            <h3>Ongoing</h3>
            <ul>
                <li><strong>Prioritize protein</strong> — aim for 1.2-1.6 g/kg body weight daily to minimize muscle loss</li>
                <li><strong>Strength training</strong> — resistance exercise preserves lean mass during weight loss</li>
                <li><strong>Monitor your diet quality</strong> — reduced appetite means each calorie counts more. Focus on nutrient-dense foods</li>
                <li><strong>Keep follow-up appointments</strong> — regular monitoring helps catch rare complications early</li>
            </ul>
        </div>

        <div class="faq-section">
            <h2>Frequently Asked Questions</h2>

            <div class="faq-item">
                <div class="faq-question">What are the most common side effects of Ozempic?</div>
                <div class="faq-answer">The most common side effects are gastrointestinal: nausea (15-20%), diarrhea (8.5%), vomiting (5-9%), constipation (3-5%), and abdominal pain (5-7%). These are most prominent during dose escalation and typically improve within 4-8 weeks.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Do Ozempic side effects go away?</div>
                <div class="faq-answer">Most GI side effects (nausea, vomiting, diarrhea) improve significantly within 4-8 weeks as your body adjusts. Gradual dose escalation helps minimize these effects. About 5% of patients in clinical trials discontinued due to GI side effects.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">What are the serious long-term risks of Ozempic?</div>
                <div class="faq-answer">Serious but rare risks include pancreatitis, gallbladder problems including gallstones, potential thyroid tumor risk (observed in animals but not confirmed in humans), diabetic retinopathy complications, and acute kidney injury usually from dehydration due to GI side effects.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Can Ozempic cause pancreatitis?</div>
                <div class="faq-answer">Pancreatitis has been reported in 0.1-0.3% of semaglutide-treated patients in clinical trials. Symptoms include severe abdominal pain radiating to the back, nausea, and vomiting. Seek immediate medical attention if you experience these symptoms.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Does Ozempic cause thyroid cancer?</div>
                <div class="faq-answer">In rodent studies, semaglutide caused thyroid C-cell tumors. This has not been confirmed in humans. The FDA has placed a boxed warning, and Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">When should I call my doctor about Ozempic side effects?</div>
                <div class="faq-answer">Call your doctor immediately for severe abdominal pain (possible pancreatitis), vision changes, signs of kidney problems, allergic reaction symptoms, a lump in your neck, or signs of severe hypoglycemia. Contact them non-urgently for persistent GI symptoms, mood changes, or hair thinning.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Does Ozempic cause muscle loss?</div>
                <div class="faq-answer">Weight loss on Ozempic includes some lean muscle mass loss — typically 30-40% of total weight lost. This is consistent with weight loss from any method. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) can help minimize muscle loss.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Can Ozempic cause depression or mood changes?</div>
                <div class="faq-answer">The FDA is investigating reports of suicidal thoughts with GLP-1 receptor agonists, though a causal link has not been established. Large-scale analyses have not found increased depression or suicidality with semaglutide. Report any mood changes to your doctor.</div>
            </div>
        </div>

        <div class="sources">
            <h3>Sources</h3>
            <ol>
                <li>FDA. "Ozempic (semaglutide) injection Prescribing Information." <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf">FDA Label</a></li>
                <li>Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." <em>N Engl J Med.</em> 2016;375(19):1834-1844. <a href="https://doi.org/10.1056/NEJMoa1607141">doi:10.1056/NEJMoa1607141</a></li>
                <li>Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." <em>N Engl J Med.</em> 2021;384:989-1002. <a href="https://doi.org/10.1056/NEJMoa2032183">doi:10.1056/NEJMoa2032183</a></li>
                <li>Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." <em>N Engl J Med.</em> 2023;389(24):2221-2232. <a href="https://doi.org/10.1056/NEJMoa2307563">doi:10.1056/NEJMoa2307563</a></li>
                <li>Wang W, et al. "Association of semaglutide with risk of suicidal ideation in a real-world cohort." <em>Nat Med.</em> 2024;30:168-176. <a href="https://doi.org/10.1038/s41591-023-02672-2">doi:10.1038/s41591-023-02672-2</a></li>
                <li>Sorli C, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo (SUSTAIN 1)." <em>Lancet Diabetes Endocrinol.</em> 2017;5(4):251-260.</li>
                <li>Novo Nordisk. "SUSTAIN clinical trial program results." <a href="https://www.novonordisk.com">novonordisk.com</a></li>
            </ol>
        </div>

        <div class="related-articles">
            <h3>Related Articles</h3>
            <a href="https://ozempic.md/how-ozempic-works">How Ozempic Works for Weight Loss: Mechanism Explained →</a>
            <a href="https://ozempic.md/ozempic-hair-loss">Does Ozempic Cause Hair Loss? What the Evidence Shows →</a>
            <a href="https://ozempic.md/what-happens-when-you-stop">What Happens When You Stop Taking Ozempic →</a>
            <a href="https://ozempic.md/ozempic-vs-mounjaro">Ozempic vs Mounjaro: Which Is Better for Weight Loss? →</a>
            <a href="https://ozempic.md/ozempic-cost">How Much Does Ozempic Cost? →</a>
            <a href="https://ozempic.md/ozempic-vs-wegovy">Ozempic vs Wegovy: Same Drug, Different Uses →</a>
        </div>
    </main>

    <footer>
        <div class="footer-inner">
            <p><a href="https://ozempic.md" class="logo" style="font-size:18px;">ozempic<span>.md</span></a></p>
            <p>Evidence-based information about Ozempic (semaglutide). Not medical advice. Always consult your healthcare provider.</p>
            <p>Part of the <a href="https://thrive.md">thrive.md</a> network. © 2026</p>
        </div>
    </footer>
</body>
</html>
